Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer

Pancreatic cancer is a recalcitrant disease. Gemcitabine (GEM) is the most widely-used first-line therapy for pancreatic cancer, but most patients eventually fail. Transformative therapy is necessary to significantly improve the outcome of pancreatic cancer patients. Tumors have an elevated requirem...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Cycle
Autors principals: Kawaguchi, Kei, Miyake, Kentaro, Han, Qinghong, Li, Shukuan, Tan, Yuying, Igarashi, Kentaro, Lwin, Thinzar M., Higuchi, Takashi, Kiyuna, Tasuku, Miyake, Masuyo, Oshiro, Hiromichi, Bouvet, Michael, Unno, Michiaki, Hoffman, Robert M.
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2018
Matèries:
Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6056209/
https://ncbi.nlm.nih.gov/pubmed/29623758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2018.1445907
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars